Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 211

1.

Improving the Youth HIV Prevention and Care Cascades: Innovative Designs in the Adolescent Trials Network for HIV/AIDS Interventions.

Naar S, Hudgens MG, Brookmeyer R, Idalski Carcone A, Chapman J, Chowdhury S, Ciaranello A, Comulada WS, Ghosh S, Horvath KJ, Ingram L, LeGrand S, Reback CJ, Simpson K, Stanton B, Starks T, Swendeman D.

AIDS Patient Care STDS. 2019 Sep;33(9):388-398. doi: 10.1089/apc.2019.0095.

PMID:
31517525
2.

Design of vaccine efficacy trials during public health emergencies.

Dean NE, Gsell PS, Brookmeyer R, De Gruttola V, Donnelly CA, Halloran ME, Jasseh M, Nason M, Riveros X, Watson CH, Henao-Restrepo AM, Longini IM.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaat0360. doi: 10.1126/scitranslmed.aat0360. Review.

3.

Overrepresentation of Injection Drug Use Route of Infection Among Human Immunodeficiency Virus Long-term Nonprogressors: A Nationwide, Retrospective Cohort Study in China, 1989-2016.

Han J, Wu Z, McGoogan JM, Mao Y, Tang H, Li J, Zhao Y, Jin C, Detels R, Brookmeyer R, Lima VD, Montaner JSG.

Open Forum Infect Dis. 2019 Apr 8;6(5):ofz182. doi: 10.1093/ofid/ofz182. eCollection 2019 May.

4.

Cross-sectional HIV incidence estimation in an evolving epidemic.

Morrison D, Laeyendecker O, Brookmeyer R.

Stat Med. 2019 Aug 30;38(19):3614-3627. doi: 10.1002/sim.8196. Epub 2019 May 21.

5.

Comprehensive Profiling of HIV Antibody Evolution.

Eshleman SH, Laeyendecker O, Kammers K, Chen A, Sivay MV, Kottapalli S, Sie BM, Yuan T, Monaco DR, Mohan D, Wansley D, Kula T, Morrison C, Elledge SJ, Brookmeyer R, Ruczinski I, Larman HB.

Cell Rep. 2019 Apr 30;27(5):1422-1433.e4. doi: 10.1016/j.celrep.2019.03.097.

6.

Design and sample size considerations for Alzheimer's disease prevention trials using multistate models.

Brookmeyer R, Abdalla N.

Clin Trials. 2019 Apr;16(2):111-119. doi: 10.1177/1740774518816323.

PMID:
30922116
7.

Cross-Sectional HIV Incidence Estimation with Missing Biomarkers.

Morrison D, Laeyendecker O, Konikoff J, Brookmeyer R.

Stat Commun Infect Dis. 2018 Dec;10(1). pii: 20170003. doi: 10.1515/scid-2017-0003. Epub 2018 Jul 31.

8.

Effects of HIV viremia on the gastrointestinal microbiome of young MSM.

Cook RR, Fulcher JA, Tobin NH, Li F, Lee D, Javanbakht M, Brookmeyer R, Shoptaw S, Bolan R, Aldrovandi GM, Gorbach PM.

AIDS. 2019 Apr 1;33(5):793-804. doi: 10.1097/QAD.0000000000002132.

PMID:
30649052
9.

Multistate models and lifetime risk estimation: Application to Alzheimer's disease.

Brookmeyer R, Abdalla N.

Stat Med. 2019 Apr 30;38(9):1558-1565. doi: 10.1002/sim.8056. Epub 2018 Dec 3.

PMID:
30511460
10.

Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies.

Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA, Bennett DA.

Ann Neurol. 2019 Jan;85(1):114-124. doi: 10.1002/ana.25380. Epub 2018 Dec 19.

PMID:
30421454
11.

Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease.

Brookmeyer R, Abdalla N.

Alzheimers Dement. 2018 Aug;14(8):981-988. doi: 10.1016/j.jalz.2018.03.005. Epub 2018 May 22.

12.

Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011-2015.

Zhao Y, Wu Z, McGoogan JM, Sha Y, Zhao D, Ma Y, Brookmeyer R, Detels R, Montaner JSG.

Clin Infect Dis. 2019 Jan 1;68(1):43-50. doi: 10.1093/cid/ciy400.

13.

Identification and validation of a multi-assay algorithm for cross-sectional HIV incidence estimation in populations with subtype C infection.

Laeyendecker O, Konikoff J, Morrison DE, Brookmeyer R, Wang J, Celum C, Morrison CS, Abdool Karim Q, Pettifor AE, Eshleman SH.

J Int AIDS Soc. 2018 Feb;21(2). doi: 10.1002/jia2.25082.

14.

Psychiatric Illness, Substance Use, and Viral Suppression Among HIV-Positive Men of Color Who Have Sex with Men in Los Angeles.

Aralis HJ, Shoptaw S, Brookmeyer R, Ragsdale A, Bolan R, Gorbach PM.

AIDS Behav. 2018 Oct;22(10):3117-3129. doi: 10.1007/s10461-018-2055-z.

15.

Brief Report: Recent Methamphetamine Use Is Associated With Increased Rectal Mucosal Inflammatory Cytokines, Regardless of HIV-1 Serostatus.

Fulcher JA, Shoptaw S, Makgoeng SB, Elliott J, Ibarrondo FJ, Ragsdale A, Brookmeyer R, Anton PA, Gorbach PM.

J Acquir Immune Defic Syndr. 2018 May 1;78(1):119-123. doi: 10.1097/QAI.0000000000001643.

16.

Simulations for designing and interpreting intervention trials in infectious diseases.

Halloran ME, Auranen K, Baird S, Basta NE, Bellan SE, Brookmeyer R, Cooper BS, DeGruttola V, Hughes JP, Lessler J, Lofgren ET, Longini IM, Onnela JP, Özler B, Seage GR, Smith TA, Vespignani A, Vynnycky E, Lipsitch M.

BMC Med. 2017 Dec 29;15(1):223. doi: 10.1186/s12916-017-0985-3.

17.

Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States.

Brookmeyer R, Abdalla N, Kawas CH, Corrada MM.

Alzheimers Dement. 2018 Feb;14(2):121-129. doi: 10.1016/j.jalz.2017.10.009. Epub 2017 Dec 7.

18.

A stochastic estimation procedure for intermittently-observed semi-Markov multistate models with back transitions.

Aralis H, Brookmeyer R.

Stat Methods Med Res. 2019 Mar;28(3):770-787. doi: 10.1177/0962280217736342. Epub 2017 Nov 8.

PMID:
29117850
19.

Immediate Antiretroviral Therapy Decreases Mortality Among Patients With High CD4 Counts in China: A Nationwide, Retrospective Cohort Study.

Zhao Y, Wu Z, McGoogan JM, Shi CX, Li A, Dou Z, Ma Y, Qin Q, Brookmeyer R, Detels R, Montaner JSG.

Clin Infect Dis. 2018 Feb 10;66(5):727-734. doi: 10.1093/cid/cix878.

20.

Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.

Lakdawalla DN, Shafrin J, Hou N, Peneva D, Vine S, Park J, Zhang J, Brookmeyer R, Figlin RA.

Value Health. 2017 Jul - Aug;20(7):866-875. doi: 10.1016/j.jval.2017.04.003. Epub 2017 May 16.

21.

A corner store intervention to improve access to fruits and vegetables in two Latino communities.

Albert SL, Langellier BA, Sharif MZ, Chan-Golston AM, Prelip ML, Elena Garcia R, Glik DC, Belin TR, Brookmeyer R, Ortega AN.

Public Health Nutr. 2017 Aug;20(12):2249-2259. doi: 10.1017/S1368980017001008. Epub 2017 Jun 5.

22.

Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations.

Moreno GA, Wang A, Sánchez González Y, Díaz Espinosa O, Vania DK, Edlin BR, Brookmeyer R.

Value Health. 2017 Jun;20(6):736-744. doi: 10.1016/j.jval.2017.01.015. Epub 2017 Feb 23.

23.

Economic study of the value of expanding HCV treatment capacity in Germany.

Sbarigia U, Wirth D, Van Nuys K, Huber C, Brookmeyer R, Stahmeyer J, Krauth C.

BMJ Open Gastroenterol. 2017 Apr 4;4(1):e000130. doi: 10.1136/bmjgast-2016-000130. eCollection 2017.

24.

Comparing Lay Community and Academic Survey Center Interviewers in Conducting Household Interviews in Latino Communities.

Chan-Golston AM, Friedlander S, Glik DC, Prelip ML, Belin TR, Brookmeyer R, Santos R, Chen J, Ortega AN.

Prog Community Health Partnersh. 2016;10(3):435-442. doi: 10.1353/cpr.2016.0050.

25.

Age of onset of hypertension and risk of dementia in the oldest-old: The 90+ Study.

Corrada MM, Hayden KM, Paganini-Hill A, Bullain SS, DeMoss J, Aguirre C, Brookmeyer R, Kawas CH.

Alzheimers Dement. 2017 Feb;13(2):103-110. doi: 10.1016/j.jalz.2016.09.007. Epub 2017 Jan 17.

26.

Measuring concurrency using a joint multistate and point process model for retrospective sexual history data.

Aralis HJ, Gorbach PM, Brookmeyer R.

Stat Med. 2016 Oct 30;35(24):4459-4473. doi: 10.1002/sim.7013. Epub 2016 Jun 20.

27.

Costs and spillover effects of private insurers' coverage of hepatitis C treatment.

Moreno GA, Mulligan K, Huber C, Linthicum MT, Dreyfus D, Juday T, Marx SE, Gonzalez YS, Brookmeyer R, Lakdawalla DN.

Am J Manag Care. 2016 May;22(6 Spec No.):SP236-44.

28.

Value of expanding HCV screening and treatment policies in the United States.

Linthicum MT, Gonzalez YS, Mulligan K, Moreno GA, Dreyfus D, Juday T, Marx SE, Lakdawalla DN, Edlin BR, Brookmeyer R.

Am J Manag Care. 2016 May;22(6 Spec No.):SP227-35.

29.

Substantial improvements not seen in health behaviors following corner store conversions in two Latino food swamps.

Ortega AN, Albert SL, Chan-Golston AM, Langellier BA, Glik DC, Belin TR, Garcia RE, Brookmeyer R, Sharif MZ, Prelip ML.

BMC Public Health. 2016 May 11;16:389. doi: 10.1186/s12889-016-3074-1.

30.

Estimating HIV incidence among key affected populations in China from serial cross-sectional surveys in 2010-2014.

Cui Y, Guo W, Li D, Wang L, Shi CX, Brookmeyer R, Detels R, Ge L, Ding Z, Wu Z.

J Int AIDS Soc. 2016 Mar 16;19(1):20609. doi: 10.7448/IAS.19.1.20609. eCollection 2016.

31.

Impact of interventions to reduce Alzheimer's disease pathology on the prevalence of dementia in the oldest-old.

Brookmeyer R, Kawas CH, Abdallah N, Paganini-Hill A, Kim RC, Corrada MM.

Alzheimers Dement. 2016 Mar;12(3):225-32. doi: 10.1016/j.jalz.2016.01.004. Epub 2016 Feb 17.

32.

The value of surrogate endpoints for predicting real-world survival across five cancer types.

Shafrin J, Brookmeyer R, Peneva D, Park J, Zhang J, Figlin RA, Lakdawalla DN.

Curr Med Res Opin. 2016;32(4):731-9. doi: 10.1185/03007995.2016.1140027. Epub 2016 Jan 25.

PMID:
26743800
33.

Broad Hepatitis C Treatment Scenarios Return Substantial Health Gains, But Capacity Is A Concern.

Van Nuys K, Brookmeyer R, Chou JW, Dreyfus D, Dieterich D, Goldman DP.

Health Aff (Millwood). 2015 Oct;34(10):1666-74. doi: 10.1377/hlthaff.2014.1193.

PMID:
26438742
34.

Simplified HIV Testing and Treatment in China: Analysis of Mortality Rates Before and After a Structural Intervention.

Wu Z, Zhao Y, Ge X, Mao Y, Tang Z, Shi CX, Chen C, Li Y, Qiu X, Nong G, Huang S, Luo S, Wu S, He W, Zhang M, Shen Z, Jin X, Li J, Brookmeyer R, Detels R, Montaner J, Wang Y.

PLoS Med. 2015 Sep 8;12(9):e1001874. doi: 10.1371/journal.pmed.1001874. eCollection 2015 Sep.

35.

Access to Care and Cardiovascular Disease Prevention: A Cross-Sectional Study in 2 Latino Communities.

Alcalá HE, Albert SL, Roby DH, Beckerman J, Champagne P, Brookmeyer R, Prelip ML, Glik DC, Inkelas M, Garcia RE, Ortega AN.

Medicine (Baltimore). 2015 Aug;94(34):e1441. doi: 10.1097/MD.0000000000001441.

36.

Sample size methods for estimating HIV incidence from cross-sectional surveys.

Konikoff J, Brookmeyer R.

Biometrics. 2015 Dec;71(4):1121-9. doi: 10.1111/biom.12336. Epub 2015 Aug 24.

37.

Combination HIV prevention among MSM in South Africa: results from agent-based modeling.

Brookmeyer R, Boren D, Baral SD, Bekker LG, Phaswana-Mafuya N, Beyrer C, Sullivan PS.

PLoS One. 2014 Nov 14;9(11):e112668. doi: 10.1371/journal.pone.0112668. eCollection 2014.

38.

Community Mobilization to Reduce Drug Use, Quang Ninh, Vietnam.

Nguyen HT, Tran AV, Nguyen NB, Nguyen SH, Vu DB, Nguyen NT, Brookmeyer RS, Detels R.

Am J Public Health. 2015 Jan;105(1):189-195.

39.

Sibanye Methods for Prevention Packages Program Project Protocol: Pilot Study of HIV Prevention Interventions for Men Who Have Sex With Men in South Africa.

McNaghten A, Kearns R, Siegler AJ, Phaswana-Mafuya N, Bekker LG, Stephenson R, Baral SD, Brookmeyer R, Yah CS, Lambert AJ, Brown B, Rosenberg E, Blalock Tharp M, de Voux A, Beyrer C, Sullivan PS.

JMIR Res Protoc. 2014 Oct 16;3(4):e55. doi: 10.2196/resprot.3737.

40.

Response to using incidence assays within the context of the recent infections testing algorithm.

Laeyendecker O, Brookmeyer R.

AIDS. 2014 Sep 10;28(14):2168. doi: 10.1097/QAD.0000000000000368. No abstract available.

PMID:
25265083
41.

Proyecto MercadoFRESCO: a multi-level, community-engaged corner store intervention in East Los Angeles and Boyle Heights.

Ortega AN, Albert SL, Sharif MZ, Langellier BA, Garcia RE, Glik DC, Brookmeyer R, Chan-Golston AM, Friedlander S, Prelip ML.

J Community Health. 2015 Apr;40(2):347-56. doi: 10.1007/s10900-014-9941-8.

42.

A serial risk score approach to disease classification that accounts for accuracy and cost.

Huynh D, Laeyendecker O, Brookmeyer R.

Biometrics. 2014 Dec;70(4):1042-51. doi: 10.1111/biom.12217. Epub 2014 Aug 25.

43.

A comparison of two measures of HIV diversity in multi-assay algorithms for HIV incidence estimation.

Cousins MM, Konikoff J, Sabin D, Khaki L, Longosz AF, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Kobin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH.

PLoS One. 2014 Jun 26;9(6):e101043. doi: 10.1371/journal.pone.0101043. eCollection 2014.

44.

Stochastic variation in network epidemic models: implications for the design of community level HIV prevention trials.

Boren D, Sullivan PS, Beyrer C, Baral SD, Bekker LG, Brookmeyer R.

Stat Med. 2014 Sep 28;33(22):3894-904. doi: 10.1002/sim.6193. Epub 2014 Apr 15.

45.

Language use affects food behaviours and food values among Mexican-origin adults in the USA.

Langellier BA, Brookmeyer R, Wang MC, Glik D.

Public Health Nutr. 2015 Feb;18(2):264-74. doi: 10.1017/S1368980014000287. Epub 2014 Apr 3.

46.

Early HIV treatment led to life expectancy gains valued at $80 billion for people infected in 1996-2009.

Romley JA, Juday T, Solomon MD, Seekins D, Brookmeyer R, Goldman DP.

Health Aff (Millwood). 2014 Mar;33(3):370-7. doi: 10.1377/hlthaff.2013.0623.

PMID:
24590933
47.

Performance of a limiting-antigen avidity enzyme immunoassay for cross-sectional estimation of HIV incidence in the United States.

Konikoff J, Brookmeyer R, Longosz AF, Cousins MM, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Justman JE, Hodder SL, Quinn TC, Eshleman SH, Laeyendecker O.

PLoS One. 2013 Dec 27;8(12):e82772. doi: 10.1371/journal.pone.0082772. eCollection 2013.

48.

HIV diversity as a biomarker for HIV incidence estimation: including a high-resolution melting diversity assay in a multiassay algorithm.

Cousins MM, Konikoff J, Laeyendecker O, Celum C, Buchbinder SP, Seage GR 3rd, Kirk GD, Moore RD, Mehta SH, Margolick JB, Brown J, Mayer KH, Koblin BA, Wheeler D, Justman JE, Hodder SL, Quinn TC, Brookmeyer R, Eshleman SH.

J Clin Microbiol. 2014 Jan;52(1):115-21. doi: 10.1128/JCM.02040-13. Epub 2013 Oct 23.

49.

Cross-sectional HIV incidence estimation in HIV prevention research.

Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH.

J Acquir Immune Defic Syndr. 2013 Jul;63 Suppl 2:S233-9. doi: 10.1097/QAI.0b013e3182986fdf.

50.

Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.

Mullis CE, Munshaw S, Grabowski MK, Eshleman SH, Serwadda D, Brookmeyer R, Nalugoda F, Kigozi G, Kagaayi J, Tobian AA, Wawer M, Gray RH, Quinn TC, Laeyendecker O.

AIDS Res Hum Retroviruses. 2013 Aug;29(8):1146-50. doi: 10.1089/AID.2012.0105. Epub 2013 May 29.

Supplemental Content

Loading ...
Support Center